GRI Bio (GRI Bio) ROE % : -493.82% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is GRI Bio ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. GRI Bio's annualized net income for the quarter that ended in Mar. 2024 was $-7.55 Mil. GRI Bio's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $1.53 Mil. Therefore, GRI Bio's annualized ROE % for the quarter that ended in Mar. 2024 was -493.82%.

The historical rank and industry rank for GRI Bio's ROE % or its related term are showing as below:

GRI' s ROE % Range Over the Past 10 Years
Min: -682.88 Med: 0 Max: 0
Current: -682.88

GRI's ROE % is ranked worse than
96.83% of 1358 companies
in the Biotechnology industry
Industry Median: -43.445 vs GRI: -682.88

GRI Bio ROE % Historical Data

The historical data trend for GRI Bio's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio ROE % Chart

GRI Bio Annual Data

Trend

Dec21

Dec22

Dec23

ROE %

GRI Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE %	Get a 7-Day Free Trial					-	-1,326.32	-272.88	-644.89	-493.82

Competitive Comparison of GRI Bio's ROE %

For the Biotechnology subindustry, GRI Bio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRI Bio's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's ROE % distribution charts can be found below:

* The bar in red indicates where GRI Bio's ROE % falls into.

GRI Bio ROE % Calculation

GRI Bio's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %	=	Net Income (A: Dec. 2023 )	/	( (Total Stockholders Equity (A: Dec. 2022 )	+	Total Stockholders Equity (A: Dec. 2023 ))	/ count )
	=	-13.037	/	( (-1.625	+	0.259)	/ 2 )
	=	-13.037	/	-0.683
	=	N/A %

GRI Bio's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %	=	Net Income (Q: Mar. 2024 )	/	( (Total Stockholders Equity (Q: Dec. 2023 )	+	Total Stockholders Equity (Q: Mar. 2024 ))	/ count )
	=	-7.548	/	( (0.259	+	2.798)	/ 2 )
	=	-7.548	/	1.5285
	=	-493.82 %

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

GRI Bio (NAS:GRI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

	ROE %		(Q: Mar. 2024 )
=	Net Income	/	Total Stockholders Equity
=	-7.548	/	1.5285
=	(Net Income / Revenue )	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-7.548 / 0)	*	(0 / 3.7715)	*	(3.7715 / 1.5285)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	N/A %	*	0	*	2.4675
=	ROA %	*	Equity Multiplier
=	N/A %	*	2.4675
=	-493.82 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

	ROE %		(Q: Mar. 2024 )
=	Net Income	/	Total Stockholders Equity
=	-7.548	/	1.5285
=	(Net Income / Pre-Tax Income)	*	(Pre-Tax Income / Operating Income)	*	(Operating Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-7.548 / -7.548)	*	(-7.548 / -7.58)	*	(-7.58 / 0)	*	(0 / 3.7715)	*	(3.7715 / 1.5285)
=	Tax Burden	*	Interest Burden	*	Operating Margin %	*	Asset Turnover	*	Equity Multiplier
=	1	*	0.9958	*	N/A %	*	0	*	2.4675
=	-493.82 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
^* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

GRI Bio ROE % Related Terms

Thank you for viewing the detailed overview of GRI Bio's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GRI Bio (GRI Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » ROE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037

Website

https://www.gribio.com

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

Executives

David Leslie Szekeres	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro	officer: Chief Medical Officer	828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz	director, 10 percent owner, officer: Chief Executive Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi	officer: Chief Scientific Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne	director	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly	officer: Chief Financial Officer	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell	director	1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc.	10 percent owner	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren	officer: SVP, Regul Affairs & Prog Mgmt	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi	director	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer	director, 10 percent owner	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon	10 percent owner	SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052